血浆miR-210联合血清肿瘤标志物对胰腺癌的诊断价值  

Diagnostic value of plasma mi R-210 combined with serum tumor markers in pancreatic cancer

作　　者：胡应霞[1] 张海蓉[1] 石围 唐君瑞[1] 

机构地区：[1]昆明医科大学第一附属医院消化内科,云南省昆明市650032

出　　处：《世界华人消化杂志》2015年第1期147-152,共6页World Chinese Journal of Digestology

基　　金：云南省科技计划基金资助项目;No.2012FB026~~

摘　　要：目的:探讨血浆m i R-210联合血清肿瘤标志物糖链抗原199(carbohydrate antigen 199,CA199)、CA242、癌胚抗原(carcino-embryonic antigen,CEA)对胰腺癌的诊断价值.方法:对60例胰腺癌患者、20例慢性胰腺炎患者及10例正常对照组的血标本进行RNA抽提,并进行mi R-210的实时PCR检测,同时对血清肿瘤标志物CA199、CA242、CEA进行检测,分析血浆mi R-210相对表达量与临床特征的关系,评估血浆mi R-210联合血清肿瘤标志物CA199、CA242、CEA对胰腺癌的诊断效能.结果:mi R-2l0在胰腺癌血浆中的相对表达量显著高于慢性胰腺炎组及正常对照组(4.12±4.51 vs 1.49±3.94,-1.73±4.82;均P<0.01),胰腺癌患者血浆m i R-21水平与C A199、C A242、C E A、肿瘤最大直径、T N M分期及临床分期无关.经二分类Logistic回归模型分析发现,血浆mi R-210单独在胰腺癌组比正常组、胰腺癌组比慢性胰腺炎组和胰腺癌组比慢性胰腺炎组+正常组中的敏感性、特异性分别为:96.7%、50.0%;95.0%、25.0%;86.7%、40.0%.血浆m i R-210联合肿瘤标志物CA199、CA242、CEA后在以上三组中的敏感性、特异性分别为:96.7%、70.0%;90.0%、85.0%;86.7%、90.0%.结论:血浆m i R-210联合血清肿瘤标志物C A199、C A242、C E A能提高胰腺癌的诊断效能.AIM： To evaluate the diagnostic value of the combination of plasma miR-210 with serum tumor markers in patients with pancreatic cancer. METHODS： Sixty patients with pancreatic cancer, twenty patients with chronic pancreatitis, and ten normal people were included in the study. Total RNA was extracted from plasma samples for measurement of miR-210 levels using real- time PCR. Simultaneously, serum tumor markers carbohydrate antigen 199 （CA199）, CA242 and carcino-embryonic antigen （CEA） were determined. The relationship between miR-210 levels and clinical characteristics of pancreatic cancer patients was analyzed. The diagnostic efficiency of combination of plasma miR-210 with serum tumor markers CA199, CA242, and CEA in pancreatic cancer patients was evaluated. RESULTS： The relative abundance of plasma miR-210 was significantly higher in the pancreatic cancer group than in the chronic pancreatitis and normal groups （4.12 ± 4.51 vs 1.49 ± 3.94, -1.73 ± 4.82; P 〈 0.01 for both）. Plasma miR-210 levels showed no significant correlation with CA199, CA242, CEA, tumor diameter, TNM stage or clinical stage in pancreatic cancer patients. Analysis using a binary logistic regression model showed that the diagnostic sensitivity and specificity of miR-210 alone were 96.7% and 50% for the pancreatic cancer group vs normal group, 95% and 25% for the pancreatic cancer group vs chronic pancreatitis group, and 86.7% and 40% for the pancreatic cancer group vs chronic pancreatitis and normal group. When plasma miR-210 was combined with serum tumor markers CA199, CA242, or CEA, the sensitivity and specificity in the three groups were 96.7% and 70%, 90% and 85%, 86.7% and 90%, respectively. CONCLUSION： The combination of plasma miR-210 with serum tumor markers CA199, CA242 or CEA can improve diagnostic efficiency in patients with pancreatic cancer.

关 键 词：血浆miR-210 血清肿瘤标志物 胰腺癌 诊断价值 

分 类 号：R735.9[医药卫生—肿瘤]